Randomised clinical trial and meta‐analysis: mesalazine treatment in irritable bowel syndrome—effects on gastrointestinal symptoms and rectal biomarkers of immune activity

BACKGROUND: Low‐grade immune activation in the gut is a potential treatment target in irritable bowel syndrome (IBS). AIMS: To determine improvement in IBS symptoms after mesalazine treatment, and the utility of measures of immune activity in the rectal mucosa METHODS: This was a randomised, double‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro Tejera, Valeria, Öhman, Lena, Aabakken, Lars, Fellström, Bengt, Hausken, Trygve, Hovde, Øistein, Hreinsson, Johann P., Lindberg, Greger, Venge, Per, Simrén, Magnus, Törnblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Mesalazine in IBS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543538/
https://www.ncbi.nlm.nih.gov/pubmed/35942522
http://dx.doi.org/10.1111/apt.17182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543538/
https://www.ncbi.nlm.nih.gov/pubmed/35942522
http://dx.doi.org/10.1111/apt.17182

Ejemplares similares